Additional Relevant Details Mast Therapeutics announced an underwritten public offering of 29,090,910 units at a price to the public of $0.275 per unit.  Each unit consists of one share of the Company's common stock and one warrant to purchase one share of the Company's common stock at an exercise price of $0.42 per share. After all expenses and underwrtiting discount, Mast expects to receive net proceeds of $7.3 million.  The public offering is expected to close on February 16, 2016.  Mast, a "biopharmaceutical company developing novel, clinical-stage therapies for sickle cell disease and heart failure", expects to use the net proceeds to fund "development programs of vepoloxamer in sickle cell disease and vepoloxamer and AIR001 in heart failure".